OnlineBusinessBureau.com
We are not the Better Business Bureau. We're better!
 
   About Us
   Our Ratings
   Look up a Company
   File a Complaint
   Complaint Resolution
     Center
   Resources
   Membership - Join Now!
   Member Login
   Testimonials
   Contact Us

1,847,257 companies
in our database.

Join our weekly
Consumer Fraud
Alert Newsletter



Our members proudly
display this seal!

News Releases

Back

New Market Study Published: Bristol-Myers Squibb Company - Product Pipeline Review - 2014

Global Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Full Report Details at
 - http://www.fastmr.com/prod/842223_bristolmyers_squibb_company_product_pipeline.aspx?afid=101

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

 * The report provides brief overview of Bristol-Myers Squibb Company including business description, key information and facts, and its locations and subsidiaries
 * The report reviews current pipeline of Bristol-Myers Squibb Company's human therapeutic division and enlists all their major and minor projects
 * The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 * Special feature on out-licensed and partnered product portfolio
 * The report summarizes all the dormant and discontinued pipeline projects
 * Latest company statement
 * Latest news and deals relating to the Bristol-Myers Squibb Company's pipeline products

Reasons to Get this Report

 * Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline
 * Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus
 * Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 * Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 * Develop strategic initiatives by understanding the focus areas of Bristol-Myers Squibb Company and exploit collaboration and partnership opportunities
 * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 * Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bristol-Myers Squibb Company
 * Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 * Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas
 * Avoid Intellectual Property Rights related issues

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Bristol-Myers Squibb Company Snapshot
Bristol-Myers Squibb Company Overview
Key Information
Key Facts
Bristol-Myers Squibb Company - Research and Development Overview
Key Therapeutic Areas
Bristol-Myers Squibb Company - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Bristol-Myers Squibb Company - Pipeline Products Glance
Bristol-Myers Squibb Company - Late Stage Pipeline Products
Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
Bristol-Myers Squibb Company - Early Stage Pipeline Products
Bristol-Myers Squibb Company - Drug Profiles
(atazanavir sulfate + cobicistat)
apixaban
asunaprevir
asunaprevir + daclatasvir
daclatasvir
(daclatasvir + asunaprevir + beclabuvir)
abatacept
beclabuvir
ipilimumab
ixabepilone
nivolumab
peginterferon lambda-1a
BMS-663068
BMS-690514
BMS-754807
BMS-813160
BMS-817399
BMS-833923
BMS-919373
BMS-954561
BMS-955176
BMS-986020
BMS-986036
censavudine
clazakizumab
dasatinib
eldelumab
lirilumab
pegdinetanib
rimegepant
Small Molecule for HIV
Triple Reuptake Inhibitors
BMS-911543
Anti-CD40 Antibody Program
Antibody Targeting CD40 Ligand for Immunology
BMS-241027
BMS-262084
BMS-394136
BMS-777607
BMS-906024
BMS-933043
BMS-936559
BMS-962476
BMS-981164
BMS-986016
BMS-986046
BMS-986089
BMS-986115
denenicokin
Iso-fludelone
MDX-1203
MDX-1303
MDX-1401
MDX-1411
Monoclonal Antibody to Antagonize CD28 for Immunology
Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
ulocuplumab
urelumab
XL-652
BMS-817378
Acrylamide (S)-6
ALB-109780
ARX-720 Relaxin
BMS-299897
BMS-457
BMS-585248
BMS-593214
BMS-795311
BMS-816106
BMS-871
Drug For Cancer
EGFR/IGFR Tandem Adnectin
EHT/AGN-0002
IPN-002
IPN-007
noscapine
Small Molecule to Inhibit Factor XIa for Thrombosis
Small Molecule to Inhibit P2Y1 for Thrombosis

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=842223&dt=t&afid=101

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available.  Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

 


Credit Secrets Bible

Get Paid for
Doing Surveys





The Online Business Bureau -- 21441 Pacific Boulevard -- Suite 200 -- Sterling, VA 20166 -- 202-558-5282
News Releases |  News Articles |  Financial Calculators |  Contact Us |  Privacy Policy | Terms of Use & Legal Notice
Copyright © 2018 Online Business Bureau, L. C.. All Rights Reserved.
We are not affiliated with the Council of Better Business Bureaus, Inc.